Your session is about to expire
← Back to Search
Pembrolizumab for Gastroesophageal Junction Adenocarcinoma
Study Summary
This trial is testing how well pembrolizumab works in treating patients with gastroesophageal adenocarcinoma.
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
- Gastric Cancer
- Esophageal Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many enrollees are part of this research endeavor?
"Affirmative. According to information hosted on clinicaltrials.gov, this medical research is actively seeking participants since its inception on February 9th 2018 and the last update was posted in December 5th 2022. This trial needs 15 individuals from a single location for participation."
Are there still opportunities to enroll in this clinical experiment?
"Affirmative, the clinicaltrials.gov website attests that this medical study is currently recruiting patients. It was initially posted on February 9th 2018 and revised on December 5th 2022. The research team seeks to enroll 15 people at one of its sites."
What types of diseases can be addressed with the administration of Pembrolizumab?
"Pembrolizumab is most frequently utilized in the treatment of malignancies. In addition, it may be prescribed to treat unresectable melanoma and microsatellite instability high conditions that have progressed despite chemotherapy treatment."
What data has been collected from previous investigations into Pembrolizumab?
"At present, clinical trials of Pembrozulizumab are being conducted in 961 different locations. Of these studies, 122 have reached Phase 3 and the overwhelming majority (36177) are located near Houston, Texas."
Share this study with friends
Copy Link
Messenger